A5032817733- Biochemical and Molecular Research
- Pancreatic and Hepatic Oncology Research
- Renal cell carcinoma treatment
- Cancer Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Urinary and Genital Oncology Studies
- Monoclonal and Polyclonal Antibodies Research
- Urological Disorders and Treatments
- Bladder and Urothelial Cancer Treatments
The First Affiliated Hospital, Sun Yat-sen University
2024-2025
Sun Yat-sen University
2024-2025
Altor BioScience (United States)
2009
Moffitt Cancer Center
2009
Sunitinib is a first-line targeted therapy for patients with renal cell carcinoma (RCC), but resistance represents significant obstacle to the treatment of advanced and metastatic RCC. Metabolic reprogramming characteristic RCC, changes in metabolic processes might contribute sunitinib. Here, we identified MTHFD2, mitochondrial enzyme involved one-carbon metabolism, as critical mediator sunitinib MTHFD2 was elevated resistant RCC cells, loss MTHDF2 conferred sensitivity In patients, highly...
<p>Figure S1-S17,Table S1-S2,Supplementary methods</p>
<div>Abstract<p>Sunitinib is a first-line targeted therapy for patients with renal cell carcinoma (RCC), but resistance represents significant obstacle to the treatment of advanced and metastatic RCC. Metabolic reprogramming characteristic RCC, changes in metabolic processes might contribute sunitinib. In this study, we identified methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), mitochondrial enzyme involved one-carbon metabolism, as critical mediator sunitinib MTHFD2 was...
<p>Sunitinib resistant cell RNA_seq data</p>
<p>MTHFD2_KD cell RNA_seq data</p>
4134 Background: CP-675,206 (tremelimumab) is a fully human monoclonal antibody which binds to the CTLA4 molecule on surface of activated T lymphocytes and regulatory cells. It thought stimulate immune system attack tumor cells by blocking negative signal CTLA4. Primary objective study determine maximum tolerated dose (MTD) evaluate safety profile in combination with gemcitabine for treatment patients previously untreated metastatic pancreatic cancer. Methods: All received 1-month...
4081 Background: Tremelimumab (CP-675206) is a fully human monoclonal antibody that binds to cytotoxic T lymphocyte-associated antigen 4 (CTLA4) on lymphocytes and regulatory cells. It thought stimulate the immune system attack tumor cells by blocking CTLA4-negative signal. The primary objective of this phase I study was determine maximum tolerated dose evaluate safety tremelimumab plus gemcitabine in pts with previously untreated metastatic pancreatic cancer. Methods: In Part A study,...
3040 Background: ALT-801 is recombinant human interleukin-2 (IL-2) genetically fused to a single-chain T-cell receptor specific peptide antigen of p53 presented in the context HLA-A2 positivity. In tumor xenografts animal models, this fusion protein demonstrated potent and targeted antitumor activity. Methods: A phase I/IIa multicenter clinical study was initiated assess safety response patients with various metastatic malignancies. Patients screened positively for tumors expressed...